Flash Finance

Dr. Lal Path Labs Ltd.LALPATHLABCorporate

Healthcare Diagnostics & Research Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹1,859.90
MCap ₹31,056 Cr · P/E 57.0
Dr. Lal Path Labs Ltd. — Stock analysis & AI research Dr. Lal Path Labs Ltd. — Seasonality — best & worst months Dr. Lal Path Labs Ltd. — Technical indicators & charts Dr. Lal Path Labs Ltd. — Technical setup — score, trend, support & resistance Dr. Lal Path Labs Ltd. — Ascending Channel pattern forming Dr. Lal Path Labs Ltd. — Live exchange announcements
📋 High ROE Stocks📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 High Profit Growth Stocks📋 Low Debt Stocks 📈 Bollinger Squeeze Stocks 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹764 Cr
Sales · Jun 2026
+19.3% YoY
₹238 Cr
Operating Profit · Jun 2026
+30.3% YoY
31.2%
OPM % · Jun 2026
+9.5% YoY
₹166 Cr
Net Profit · Jun 2026
+28.6% YoY
₹9.94
EPS · Jun 2026
+28.9% YoY

📝 Dr. Lal Path Labs Ltd. — results explained

Quarter ended June 2026 (Q1 FY27)

Dr. Lal Path Labs Ltd. reported revenue of ₹764 crore for the quarter ended June 2026 (Q1 FY27), up 19.3% from ₹641 crore in the same quarter last year, and up 13.2% sequentially over the March 2026 quarter.

Net profit rose 28.6% year-on-year to ₹166 crore, from ₹129 crore. Earnings per share (EPS) came in at ₹9.94.

Operating profit stood at ₹238 crore — an operating margin (OPM) of 31.2%, compared with 28.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Dr. Lal Path Labs Ltd. posted revenue of ₹2,648 crore, a growth of 19.1% over FY25, with a net profit of ₹508 crore (down 2.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,772 crore with a net profit of ₹545 crore.

Valuation snapshot

At the current price of ₹1,859.90, LALPATHLAB has a market capitalisation of ₹31,056 crore and a trailing P/E of about 57.0.

Within the Diagnostics & Research industry, it is the 2nd-largest of the 3 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 52.93%, foreign institutional investors (FIIs) 18.73%, domestic institutional investors (DIIs) 21.58%, public shareholders 6.35% of Dr. Lal Path Labs Ltd..

Promoter holding slipped from 53.19% to 52.93% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹31,056 Cr
Current Price ?
₹1,859.9
P/E ?
56.98below ind
Industry P/E ?
70.20
P/B ?
12.56
P/S ?
11.21
P/FCF ?
71.23
Enterprise Value ?
₹31,249 Cr
EV/EBITDA ?
38.62
PEG ?
2.59
Earnings Yield ?
2.1%
Dividend Yield ?
0.77%
Profitability & Returns
Sales (TTM) ?
₹2,772 Cr
OPM ?
29.2%
Profit after tax (TTM) ?
₹545 Cr
EPS (TTM) ?
₹32.64
ROCE ?
29.0%
ROE ?
22.0%
ROA ?
17.9%
Growth
Sales — latest qtr ?
₹764 Cr
PAT — latest qtr ?
₹166 Cr
YoY qtr sales growth ?
19.3%
YoY qtr profit growth ?
28.6%
Sales growth (3y) ?
14%
Sales growth (5y) ?
12%
Profit growth (3y) ?
22%
Profit growth (5y) ?
14%
Financial Health
Debt ?
₹193 Cr
Debt to Equity ?
0.08
Interest Coverage ?
27.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
52.93%
Change in promoter holding ?
-0.86%
Pledged percentage ?
N/A
Market
Return 3 months ?
10.2%
Return 6 months ?
32.7%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 431480532476479534584528577641700632675764 +19.3% +13.2%
Operating Profit 116136163130130156184145159183215174182238 +30.3% +31.0%
Other Income 1215141516292230252623273730 +15.0% -19.2%
Interest 87766655545766 +52.5% +1.7%
Depreciation 2118191920181819353338404340 +21.2% -7.0%
Profit Before Tax 98125151120120161183151145172195123170222 +29.2% +30.8%
Net Profit 7194113889012313511414812914692141166 +28.6% +17.7%
EPS 8.6111.2813.605.2910.7314.7616.2413.7417.807.718.695.528.429.94 +28.9% +18.1%
OPM % 26.8% 28.3% 30.7% 27.3% 27.2% 29.1% 31.6% 27.5% 27.6% 28.5% 30.7% 27.5% 27.0% 31.2% +9.5% +15.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,224 Cr ₹2,648 Cr ₹2,772 Cr +19.1%
Operating Profit ₹644 Cr ₹754 Cr ₹809 Cr +16.9%
OPM % 28.98% 28.46% 29.20% -1.8%
NPM % 23.43% 19.19% 19.66% -18.1%
Other Income ₹106 Cr ₹113 Cr ₹116 Cr +6.7%
Depreciation ₹90 Cr ₹154 Cr ₹161 Cr +72.2%
Interest ₹20 Cr ₹22 Cr ₹24 Cr +9.5%
EBIT ₹555 Cr ₹600 Cr ₹648 Cr +8.0%
PBT ₹640 Cr ₹660 Cr ₹710 Cr +3.1%
Tax ₹119 Cr ₹31 Cr ₹87 Cr -74.0%
Net Profit ₹521 Cr ₹508 Cr ₹545 Cr -2.5%
EPS ₹62.54 ₹30.34 ₹32.57 -51.5%
Material Cost ₹428 Cr ₹122 Cr ₹266 Cr -71.5%
Employee Cost ₹428 Cr ₹127 Cr ₹252 Cr -70.2%
Extraordinary Items — ₹-30 Cr ₹-30 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 838384168 +100.0%
Reserves 1,6061,7172,0512,305 +12.4%
Borrowings 28114253193 +264.2%
Other Liabilities 350406434383 -11.8%
Total Liabilities 2,3202,3492,6213,049 +16.3%
Fixed Assets 3611,1041,0511,144 +8.8%
CWIP 5636 +100.0%
Investments 1,213213416513 +23.3%
Other Assets 7401,0261,1511,386 +20.4%
Total Assets 2,3202,3492,6213,049 +16.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 428478540606 +12.2%
Cash from Investing Activity -28832-293-382 -30.4%
Cash from Financing Activity -270-404-325-256 +21.2%
Net Cash Flow -131106-78-32 +59.0%
Free Cash Flow 390429488436 -10.7%
CFO/OP 114%104%104%102% -1.9%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 13151618 +12.5%
Inventory Days 22282629 +11.5%
Days Payable 131154155126 -18.7%
Cash Conversion Cycle -96-111-113-79 +30.1%
Working Capital Days -61-46-2830 +207.1%
ROCE % 22%26%31%29% -6.5%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 53.79%53.21%53.21%53.21%53.19%52.93% -0.5%
FIIs 21.69%21.86%20.29%17.18%17.36%18.73% +7.9%
DIIs 17.62%18.22%19.20%21.37%21.59%21.58% -0.0%
Government 0.29%0.27%0.01%0.01%0.01%— —
Public 6.22%6.07%6.94%7.88%7.47%6.35% -15.0%
Others 0.39%0.37%0.35%0.34%—— —
No. of Shareholders 1,18,6561,12,7031,16,1671,14,5271,11,0371,13,559 +2.3%

⚖️ Peer comparison

Industry: Diagnostics & Research · 3 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SAILIFE SAI LIFE ₹1,585.00 33,664 95.7 2,181 343 29.0% 15.7% 29.4% 105.3% 3.8% 18.2%
2 LALPATHLAB Dr. Lal ₹1,897.00 31,676 58.5 2,892 546 29.0% 18.9% 12.3% 3.4% 19.1% 27.2%
3 SYNGENE Syngene International ₹383.10 15,420 69.8 3,600 221 22.3% 6.1% 2.6% -36.2% -15.8% -110.4%
❓ Frequently asked questions
What was Dr. Lal Path Labs Ltd.'s revenue in Q1 FY27?
Dr. Lal Path Labs Ltd. reported revenue of ₹764 crore for the quarter ended June 2026 (Q1 FY27), up 19.3% from ₹641 crore in the same quarter last year, and up 13.2% sequentially over the March 2026 quarter.
What was Dr. Lal Path Labs Ltd.'s net profit in Q1 FY27?
Net profit rose 28.6% year-on-year to ₹166 crore, from ₹129 crore. Earnings per share (EPS) came in at ₹9.94.
What is LALPATHLAB's market capitalisation and P/E ratio?
At the current price of ₹1,859.90, LALPATHLAB has a market capitalisation of ₹31,056 crore and a trailing P/E of about 57.0.
Who owns Dr. Lal Path Labs Ltd.? (shareholding pattern)
As of Sep 2026, promoters held 52.93%, foreign institutional investors (FIIs) 18.73%, domestic institutional investors (DIIs) 21.58%, public shareholders 6.35% of Dr. Lal Path Labs Ltd..
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI